Patent · US Active

Method of treating melanocortin-4 receptor pathway-associated disorders

US10960046B2 · kind B2 · utility

0Cited by

1References

8Claims

0Family size

Assignees

RHYTHM PHARMACEUTICALS, INC. · US
CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN · DE

Inventors

Leonardus H. T. Van Der Ploeg · Newton, US
Bart Henderson · Belmont, US
Peter Kuhnen · Berlin, DE

Key dates

Filing date	Sep 29, 2016
Grant date	Mar 30, 2021
Priority date	—
Expiry date	Sep 29, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure is related to a method of treating a disorder, such as Prader Willi Syndrome (PWS), obesity or hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist. Also described is method of treating a subject having a deficiency in the pro-opiomelanocortin (POMC)-MC4R pathway, such as a POMC-null or a PCSK-null subject, using a MC4R agonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.